Trial reportAmerican journal of hypertension2023
Blood Pressure Variability and Cognitive Decline: A Post Hoc Analysis of the SPRINT MIND Trial.
Trial report in American journal of hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01206062 (Systolic Blood Pressure Intervention Trial), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Systolic Blood Pressure Intervention Trial
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Comparison of visit-to-visit blood pressure variability and time in target range in predicting risk for cognitive outcomes in the SPRINT trial.Journal of Alzheimer's disease : JAD · 2025Trial
- 24-Hour Blood Pressure Variability Via Ambulatory Monitoring and Risk for Probable Dementia in the SPRINT Trial.The journal of prevention of Alzheimer's disease · 2024Trial
- Blood Pressure Variability and Cerebral Perfusion Decline: A Post Hoc Analysis of the SPRINT MIND Trial.Journal of the American Heart Association · 2023Trial
- Visit-to-visit systolic blood pressure variability, blood pressure treatment intensity, and cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Exposome influences: a multi-omics perspective on the combined toxic effects of pharmaceuticals and personal care products in Alzheimer's disease.Frontiers in toxicology · 2026Review
- Article
- Blood pressure and the brain: the conundrum of hypertension and dementia.Cardiovascular research · 2025Review
- Beyond the beats: exploring the link between blood pressure fluctuations with anxiety, depression, and sleep.Frontiers in psychiatry · 2025Article
- Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Hypertension, Neurodegeneration, and Cognitive Decline.Hypertension (Dallas, Tex. : 1979) · 2024Review
- A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review PART II-Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory.Journal of clinical medicine · 2024Review
- Short-term blood pressure variability and brain functional network connectivity in older adults.Neuroimage. Reports · 2024Article
- Heart Rate Variability and Cognition: A Narrative Systematic Review of Longitudinal Studies.Journal of clinical medicine · 2024Review
- Blood Pressure Variability and Plasma Alzheimer's Disease Biomarkers in the SPRINT Trial.Journal of Alzheimer's disease : JAD · 2024Article
- Blood pressure variability, central autonomic network dysfunction and cerebral small vessel disease in APOE4 carriers.medRxiv : the preprint server for health sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBlood pressure (BP) variability (BPV) is an emerging risk factor for cognitive impairment and dementia, but relationships with cognition in the context of antihypertensive strategies remain unclear. We examined whether visit-to-visit BPV relates to cognitive change based on antihypertensive treatment type.
methodsIn this post hoc analysis of the SPRINT MIND trial, 2,348 participants underwent 4 BP measurements over a 9-month period after treatment randomization (standard vs. intensive BP lowering) and ≥ 1 neuropsychological evaluation thereafter. BPV was calculated as tertiles of BP SD. Participants underwent cognitive testing at baseline and every 2 years during the planned 4-year follow-up. Cognitive composite scores were calculated for global cognition, memory, language, executive function, and processing speed. Linear mixed models investigated relationships between BPV, antihypertensive treatment group, and time on cognitive composite scores.
resultsElevated BPV was associated with the fastest decline in processing speed (ß = -.07 [95% CI -.12, -.01]; P = 0.02) and executive function (ß = -.08 [95% CI -.16, -.006]; P = 0.03) in the standard treatment group only. BPV was not related to cognitive change in the intensive treatment group. Mean/minimum/maximum BP was not associated with cognitive composite scores over time in either antihypertensive treatment group.
conclusionsElevated BPV remains a risk for cognitive decline despite strictly controlled BP levels, in the standard treatment group. Specific declines were observed in processing speed and executive function, domains often impacted by cerebrovascular disease and may underpin risk for dementia and cerebrovascular disease associated with BPV. Clinical trial information: ClinicalTrials.gov; NCT01206062.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.